Atai Life Sciences
Business Services · Germany · 83 Employees
View Company Info for Free
About
Headquarters
16 Wallstrasse, Berlin, Berlin, 10179, GermanyPhone Number
+49 8921539035Website
atai.lifeRevenue
<$5 MillionStock Symbol
ATAIIndustry
Most Recent Scoops
Highlights
$774M
Total Funding Amount
$175M
Most Recent Funding Amount
7
Number of Funding Rounds
Who is Atai Life Sciences
Atai Life Sciences Org Chart
Is Atai Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Atai Life Sciences recently announced quarterly report
Check if Atai Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if Atai Life Sciences had a recent Job posting/layoffs
Atai Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Atai Life Sciences has new funding data
Product Launch: Get notified when Atai Life Sciences launches new products
Congratulate Masked Content for being promoted to Masked Content at Atai Life Sciences
Check out if Atai Life Sciences is spiking on competitors!
Recommended Actions
Find VP level buyers at Atai Life Sciences
Find 2 more new buyers
Atai Life Sciences financials insights
Gather financial insights about Atai Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Atai Life Sciences Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Atai Life Sciences Tech Stack
A closer look at the technologies used by Atai Life Sciences
Most Recent Scoops
Atai Life Sciences News & Media
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering wiatai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three monthsatai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officeratai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company’s participation:
Top Companies in Germany
Top 10 companies in Germany by revenue
Top 10 companies in Germany by number of employees
Top 10 companies in Germany by total funding amount
Frequently Asked Questions Regarding Atai Life Sciences
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clin... Read More